Paris-based Resilience, a specialist in remote monitoring of cancer patients, has raised €48 million from the American fund PSG Equity, in a deal revealed on 5 November 2026. The money is meant to let it move beyond oncology to also monitor patients in psychiatry and gastroenterology, expand abroad and acquire competitors. It is a bet on the ability of a care model born in hospitals to scale up.
€48M from PSG Equity
According to mind Health, the news was first published by Les Echos on 5 November. The French Tech Journal describes an equity growth round led by PSG Equity, and specifies that a takeover has not been established. Dealroom puts the deal at $53.5 million and says it brings the total raised by the company since 2021 to more than €105 million. In its round-up published on 13 November, Maddyness ranks it as the largest French funding round of the week.
The deal carries weight on the scale of the sector. According to Dealroom data, it sits in the 91st percentile of French digital health growth rounds over the past four years, among 78 comparable deals. The platform also notes, citing France Biotech, that digital health funding reached €1 billion in France in 2025, but that only one company in five managed to raise funds: the money is becoming concentrated.
What Resilience does
Co-founded by Céline Lazorthes and Jonathan Benhamou with the Gustave Roussy Institute, Resilience combines, according to the French Tech Journal, clinical monitoring software for care teams and a mobile app for patients. The principle of remote monitoring is to maintain a regular link between the medical team and the patient between two consultations.
According to the French Tech Journal, which reports figures provided by the company, the platform has already supported more than 40,000 cancer patients in some 200 healthcare facilities in France, and has twelve partner facilities in Germany. The company profile maintained by mind Health notes that it has been led since March 2025 by Arthur Thirion, and that it has multiplied partnerships, with Bayer, with Bristol Myers Squibb around CAR-T therapies, and with Gustave Roussy for clinical research.
Moving beyond cancer: psychiatry and gastroenterology
The use of funds is explicit. Resilience wants to extend its monitoring to psychiatry and gastroenterology, accelerate internationally and make acquisitions, in particular of companies that already benefit from established reimbursement, according to the French Tech Journal. The company has already started: in September 2026 it acquired Recovery Cat, a German psychiatric monitoring start-up. It has also recruited a sales team in the United States. Mind Health, which now presents it as a “multi-condition” remote monitoring company, had published as early as April 2025 an interview in which its chief executive mentioned entering the American market by 2026.
On the financial side, the company says it is aiming for profitability at group level by the second quarter of 2027, according to the French Tech Journal and Dealroom.
What it changes for patients and hospitals
For healthcare facilities, the arrival of a better-funded player present across several specialties can simplify things: a single tool to monitor oncology, psychiatry or gastroenterology patients, rather than one app per department. For patients with chronic diseases, the expansion means that monitoring between consultations, until now offered mainly in oncology, could become more common in other disciplines.
The stated interest in acquiring companies that are already reimbursed is telling: it suggests that the business model relies largely on coverage by health systems, country by country. An acquisition saves time on this often lengthy step.
The questions that remain open
Several points do not appear in any of the sources consulted: revenue, valuation and the size of PSG Equity’s stake. The entry of an American private equity fund into a company that processes the health data of French patients also raises the question of governance, even though none of the sources reports a change of control. Finally, success in psychiatry, where care pathways differ greatly from those in oncology, remains to be demonstrated. Dealroom sums up the stakes: this round is a major bet on the ability of a care model to expand to other conditions and other countries.
Frequently asked questions
How much did Resilience raise, and from whom?
The company raised €48 million from the American fund PSG Equity, the only investor named. According to Dealroom, it has raised more than €105 million since 2021.
What is the Resilience platform for?
It allows care teams to remotely monitor the condition of patients with chronic diseases, starting with oncology, through an app for patients and clinical monitoring software for care teams, according to the French Tech Journal.
Which new specialties are targeted?
Psychiatry and gastroenterology, according to the French Tech Journal. The acquisition of the German company Recovery Cat, in September 2026, is the first step on the psychiatry side.
Sources
- French Tech Funding Wire: Resilience Care's €48M Led 11 Deals For €81.8M — French Tech Journal, 2026-11-09
- France's Resilience raises €48M to expand beyond cancer care — Dealroom News, 2026-11-09
- Resilience lève 48 M€ — mind Health, 2026-11-09
- Resilience — fiche entreprise — mind Health, 2026-11-09
- Les startups françaises ont levé 118 millions d'euros cette semaine — Maddyness, 2026-11-13